# Novo Nordisk launches cheaper Ozempic in South Africa — retained record

> Retained news record from news:semafor.

Canonical: https://highsignal.app/data/records/f3b07eab54a198d6

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:semafor)  published 2026-07-20 12:52 ingested 2026-07-21 08:20

[original source ↗](https://www.semafor.com/article/07/20/2026/novo-nordisk-announces-low-cost-ozempic-drug-in-south-africa)

## retained text



```
Danish pharmaceutical giant Novo Nordisk has launched South Africa’s first low-cost version of its weight-loss drug, in a bid to squeeze out counterfeit products in Africa’s most obese nation.
Demand for the drug, first developed for diabetes before becoming a global weight-loss phenomenon, has exploded. Some branded versions such as Ozempic can cost hundreds of dollars a month — prohibitively expensive for many — and that affordability gap opened the floodgates for unregulated weight-loss medications.
The new product will be “cheaper” than its main brand, said Sara Narcross, Nordisk’s South Africa head. The launch last week follows a court victory for Nordisk against local compounding pharmacies making unauthorized copies. South Africa has the highest adult obesity rate in Africa, with roughly 30% of adults classified as living with obesity. The burden hits women hardest, with nearly seven in 10 adult women considered overweight or obese.
```



document fetched 2026-07-21 08:20 · canonical https://semafor.com/article/07/20/2026/novo-nordisk-announces-low-cost-ozempic-drug-in-south-africa